318 related articles for article (PubMed ID: 35456994)
1. Neuromelanin in Parkinson's Disease: Tyrosine Hydroxylase and Tyrosinase.
Nagatsu T; Nakashima A; Watanabe H; Ito S; Wakamatsu K
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456994
[TBL] [Abstract][Full Text] [Related]
2. The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease.
Nagatsu T; Nakashima A; Watanabe H; Ito S; Wakamatsu K; Zucca FA; Zecca L; Youdim M; Wulf M; Riederer P; Dijkstra JM
J Neural Transm (Vienna); 2023 May; 130(5):611-625. PubMed ID: 36939908
[TBL] [Abstract][Full Text] [Related]
3. Catecholamines and Parkinson's disease: tyrosine hydroxylase (TH) over tetrahydrobiopterin (BH4) and GTP cyclohydrolase I (GCH1) to cytokines, neuromelanin, and gene therapy: a historical overview.
Nagatsu T
J Neural Transm (Vienna); 2024 Jun; 131(6):617-630. PubMed ID: 37638996
[TBL] [Abstract][Full Text] [Related]
4. Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis.
Carballo-Carbajal I; Laguna A; Romero-Giménez J; Cuadros T; Bové J; Martinez-Vicente M; Parent A; Gonzalez-Sepulveda M; Peñuelas N; Torra A; Rodríguez-Galván B; Ballabio A; Hasegawa T; Bortolozzi A; Gelpi E; Vila M
Nat Commun; 2019 Mar; 10(1):973. PubMed ID: 30846695
[TBL] [Abstract][Full Text] [Related]
5. The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells.
Pan T; Zhu J; Hwu WJ; Jankovic J
PLoS One; 2012; 7(9):e45183. PubMed ID: 23028833
[TBL] [Abstract][Full Text] [Related]
6. Riddles in the dark: Decoding the relationship between neuromelanin and neurodegeneration in locus coeruleus neurons.
Iannitelli AF; Weinshenker D
Neurosci Biobehav Rev; 2023 Sep; 152():105287. PubMed ID: 37327835
[TBL] [Abstract][Full Text] [Related]
7. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ
Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211
[TBL] [Abstract][Full Text] [Related]
8. The enigma of neuromelanin in Parkinson's disease substantia nigra.
Youdim MB; Ben-Shachar D; Riederer P
J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
[TBL] [Abstract][Full Text] [Related]
9. Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.
Asanuma M; Miyazaki I; Ogawa N
Neurotox Res; 2003; 5(3):165-76. PubMed ID: 12835121
[TBL] [Abstract][Full Text] [Related]
10. Cooperative synthesis of dopamine by non-dopaminergic neurons as a compensatory mechanism in the striatum of mice with MPTP-induced Parkinsonism.
Kozina EA; Kim AR; Kurina AY; Ugrumov MV
Neurobiol Dis; 2017 Feb; 98():108-121. PubMed ID: 27940203
[TBL] [Abstract][Full Text] [Related]
11. ser31 Tyrosine hydroxylase phosphorylation parallels differences in dopamine recovery in nigrostriatal pathway following 6-OHDA lesion.
Salvatore MF
J Neurochem; 2014 May; 129(3):548-58. PubMed ID: 24410633
[TBL] [Abstract][Full Text] [Related]
12. Effect of siRNA-induced silencing of cellular prion protein on tyrosine hydroxylase expression in the substantia nigra of a rat model of Parkinson's disease.
Wang X; Yang HA; Wang XN; Du YF
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173342
[TBL] [Abstract][Full Text] [Related]
13. Preclinical signs of Parkinson's disease: A possible association of Parkinson's disease with skin and hair features.
Jucevičiūtė N; Banaitytė I; Vaitkus A; Balnytė R
Med Hypotheses; 2019 Jun; 127():100-104. PubMed ID: 31088630
[TBL] [Abstract][Full Text] [Related]
14. DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease.
Cai W; Wakamatsu K; Zucca FA; Wang Q; Yang K; Mohamadzadehonarvar N; Srivastava P; Tanaka H; Holly G; Casella L; Ito S; Zecca L; Chen X
Prog Neurobiol; 2023 Apr; 223():102414. PubMed ID: 36746222
[TBL] [Abstract][Full Text] [Related]
15. Human tyrosine hydroxylase in Parkinson's disease and in related disorders.
Nagatsu T; Nakashima A; Ichinose H; Kobayashi K
J Neural Transm (Vienna); 2019 Apr; 126(4):397-409. PubMed ID: 29995172
[TBL] [Abstract][Full Text] [Related]
16. [Synthesis of monoamines by non-monoaminergic neurons: illusion or reality?].
Ugrumov MV
J Soc Biol; 2009; 203(1):75-85. PubMed ID: 19358813
[TBL] [Abstract][Full Text] [Related]
17. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Chu Y; Kordower JH
Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
[TBL] [Abstract][Full Text] [Related]
18. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects.
Nagatsu T; Sawada M
J Neural Transm Suppl; 2007; (72):113-20. PubMed ID: 17982884
[TBL] [Abstract][Full Text] [Related]
19. Melanin and Neuromelanin: Linking Skin Pigmentation and Parkinson's Disease.
Krainc T; Monje MHG; Kinsinger M; Bustos BI; Lubbe SJ
Mov Disord; 2023 Feb; 38(2):185-195. PubMed ID: 36350228
[TBL] [Abstract][Full Text] [Related]
20. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease.
Zucca FA; Segura-Aguilar J; Ferrari E; Muñoz P; Paris I; Sulzer D; Sarna T; Casella L; Zecca L
Prog Neurobiol; 2017 Aug; 155():96-119. PubMed ID: 26455458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
